Thirst in stable heart failure patients; time to reconsider fluid restriction and prescribed diuretics

Martje H.L. van der Wal1,2, Tiny Jaarsma1,3*, Lieset C. Jenneboer4 and Gerard C.M. Linssen5

1Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden; 2Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 3Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; 4Department of Cardiology, Hospital Group Twente (Almelo and Hengelo), Almelo, The Netherlands; 5Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden;

Abstract

Aims One of the bothersome symptoms that heart failure (HF) patients can experience is thirst. There are limited data on the association between thirst and fluid intake and clinical variables. Therefore, the aim of this study was to describe severe thirst in stable HF patients and assess factors related to severe thirst, including actual fluid intake and sodium intake.

Methods and results The study had a cross-sectional design. Stable HF patients from two HF clinics in the Netherlands were included and assessed thirst by a visual analogue scale ranging from 0 to 100. They also completed questionnaires on thirst distress, self-care behaviour, and HF symptoms. A 3 day food diary was completed to assess actual fluid intake and sodium intake. Finally, patients collected urine for 24 h. Patients were divided into severe and low thirst based on thirst score and thirst distress. T-tests, Mann–Whitney tests, and χ² tests were conducted to assess differences between both groups. Multivariable logistic regression analysis was performed to assess factors associated with severe thirst. A total of 100 patients were included (40% female, mean age 72 ± 12) of which 68 completed the food diary. The mean thirst score was 28 ± 25, and 25% experienced severe thirst. The majority of patients (94%) were prescribed a fluid restriction, 37% had a restriction between 1500 and 2000 mL, and 32% a restriction of 1500 mL. Severe thirst in the total group with 100 patients was associated with a higher dose of loop diuretics [odds ratio (OR) 3.25; 95% confidence interval (CI) 1.00–10.45; P = 0.048 and a higher urine output over 24 h (OR 1.002; 95% CI 1.00–1.003; P = 0.010). In the group of patients who completed the food diary (N = 68), severe thirst was associated with a higher sodium intake (OR 1.002; 95% CI 1.001–1.003; P = 0.003), a higher dose of loop diuretics (OR 22.69; 95% CI 2.78–185.04; P = 0.004), and more fatigue (OR 11.2; 95% CI 1.54–82.12; P = 0.017).

Conclusions A quarter of all stable HF patients experienced severe thirst. A higher dose of loop diuretics was associated with more thirst; therefore, it might be important to review the dose of loop diuretics critically and try to decrease it in order to relieve severe thirst. Because all patients were prescribed a fluid restriction, a reconsideration of this restriction is also suggested.

Keywords Thirst; Heart failure; Fluid restriction; Sodium intake

Introduction

Treatment of patients with heart failure (HF) has improved substantially and resulted in improved survival rates.1 However, many HF patients experience poor quality of life with symptoms of fatigue, dyspnoea, and periods of fluid retention.1–3 In addition, bothersome symptoms that HF patients may experience are for example depressive symptoms, lack of appetite, and thirst.4–6 Thirst can be described as ‘a deep sensation or desire for water that cannot be ignored and causes a powerful behavioural strive to drink water’.7 Severe thirst is a troublesome symptom, which can decrease the quality of life and can cause distress.5,8,9 From limited data in small studies on thirst in HF patients, it is found that thirst can be related to the HF treatment, for example the HF regimen (dose of diuretics or prescribed fluid restriction) and the severity of the disease.5 Furthermore, stable HF patients experienced less thirst compared with patients with worsening HF, and their thirst intensity might change in different stages of optimization of HF medication.10
It is also described that thirst can be related to other HF symptoms, and in one small study, thirst was related to the level of anxiety. There is an ongoing debate on the role of fluid restriction in HF management. However, in most of the studies on thirst, the prescribed fluid restriction was taken into account, and only in a limited number of studies, the actual fluid intake was assessed.

There is only scarce data about the relationship between (severe) thirst, actual fluid intake, and other variables that can be related to thirst in a stable HF population.

Therefore, the aim of the present study was (1) to describe severe thirst in stable, ambulatory HF patients and (2) to assess factors related to severe thirst, including fluid intake and sodium intake in a stable HF outpatient population. In addition, urinary 24 h volumes and sodium were analysed.

Methods

A cross-sectional study was conducted in two outpatient HF clinics (Hospital Group Twente in Almelo and Hengelo) in the Netherlands. Patients were recruited from January 2017 to November 2018. Inclusion criteria were having a diagnosis of chronic HF in New York Heart Association (NYHA) functional classes II–IV, in a stable condition (defined as no admission, Emergency Room visit, or change in loop diuretics 4 weeks before inclusion), older than 18 years, and able to read and write in Dutch. Important exclusion criteria were included in another (medication) trial, on haemodialysis, or on the waiting list for heart transplantation.

Patients received written information about the study a week before their visit at the HF clinic. After further oral information at the HF clinic, they signed written informed consent.

All patients assessed thirst on a visual analogue scale (VAS) ranging from 0 (no thirst) to 100 (worst possible thirst). Thirst distress was measured with the Thirst Distress Scale-HF, a validated questionnaire consisting of nine statements about thirst. Patients were asked to rate the items from 1 (strongly disagree) to 5 (strongly agree).

The 9-item European Heart Failure Self-care Behaviour Scale was used to measure self-care behaviour, including behaviours like restricting fluid intake, regular exercise, or consulting behaviour. Patients also assessed whether or not they experienced the following HF symptoms (yes/no): oedema, dyspnoea, fatigue, sleeping problems, and cough.

For the assessment of fluid intake and sodium intake, patients were asked to complete a food diary for three consecutive days (with 1 day during the weekend), writing down everything they ate or drank. Finally, they were asked to collect urine for 24 h.

Baseline characteristics were collected from the patients’ medical chart, and HF symptoms were self-reported by the patient. The dose of loop diuretics was calculated as an equivalent dose of furosemide.

The Medical Ethical Committee of the University Medical Centre Groningen in the Netherlands stated that no additional approval of the committee was needed (METC 2016/229).

Analysis

Descriptive statistics were used to characterize the study population. Patients were divided into severe thirst and low thirst, where severe thirst was defined as a VAS score on thirst above 49 (mean theoretical score of the scale) and/or if patients (strongly) agreed with statement 8 of the Thirst Distress Scale (‘I am so thirsty I could drink water uncontrollably’).

The food diary was analysed by one of the co-authors (LJ) using a special programme of the Dutch Nutrition Centre (‘Eetmeter’) to calculate nutrients.

Normality of continuous variables was assessed by Kolmogorov–Smirnov. To assess differences between patients with severe and low thirst, $\chi^2$ tests and t-tests were conducted. For continuous variables that were not normally distributed, Mann–Whitney tests were used. Multivariable logistic regression analyses were performed to assess which variables were independently related to severe thirst. Variables with a $P < 0.05$ were inserted in the regression model.

SPSS Statistics 23 was used for all analyses

Because there was limited time for the study, we decided with both HF clinics that 100 patients should be included in...
this observational study. Therefore no formal power calculation was performed.

All analyses were performed for the total group of patients \( (N = 100) \) and separately for patients who completed a food diary \( (N = 68) \).

## Results

A total of 384 patients were approached to participate in the study of which 100 gave informed consent and were included in the study. The main reasons for exclusion were that patients did not want to participate (43%), were not in a stable condition (26%), or were not in NYHA-functional classes II–IV (13%) (Figure 1).

The mean age of the study population was 72 ± (standard deviation) 12 years, 40% were female and most of the patients were in NYHA-functional class II (74%; \( N = 74 \)). The mean dose of loop diuretics was 63 ± 51 mg of furosemide; one-third of the patients were prescribed more than 40 mg of furosemide/day. The mean dose of mineralocorticoid receptor antagonist was 21 ± 11 mg. There were only two patients who used another diuretic.

### Table 1 Characteristics of all HF patients in the study \( (N = 100) \)

|                      | All patients \( (N = 100) \) | Severe thirst \( (N = 25) \) | Low thirst \( (N = 75) \) | \( P \) value |
|----------------------|-----------------------------|-----------------------------|--------------------------|-------------|
| Age ± SD             | 72 ± 12                     | 72 ± 13                     | 72 ± 11                  | NS          |
| Female sex           | 40% (40)                    | 32% (8)                     | 43% (32)                 | NS          |
| Thirst score ± SD    | 28 ± 25                     | 53 ± 29                     | 18 ± 15                  | <0.01       |
| NYHA class           |                             |                             |                          |             |
| II                   | 74% (74)                    | 68% (17)                    | 76% (57)                 | NS          |
| III–IV (>NYHA II)    | 23% (23)                    | 28% (7)                     | 21% (16)                 | NS          |
| LVEF ± SD            | 39 ± 13                     | 40 ± 18.2                   | 39 ± 11.8                | NS          |
| LVEF < 40%           | 53%                         | 48% (12)                    | 55% (41)                 | NS          |
| LVEF > 40%           | 38%                         | 40% (10)                    | 37% (28)                 | NS          |
| Ischaemic heart disease | 45% (45)                    | 36% (9)                     | 48% (36)                 | NS          |
| HF symptoms           |                             |                             |                          |             |
| Dyspnoea at rest     | 20% (20)                    | 36% (9)                     | 15% (11)                 | NS          |
| Dyspnoea exercise    | 67% (67)                    | 80% (20)                    | 63% (47)                 | NS          |
| Fatigue              | 39% (39)                    | 64% (16)                    | 31% (23)                 | 0.015       |
| Sleeping problems    | 26% (26)                    | 36% (9)                     | 23% (17)                 | NS          |
| Total HF symptoms ± SD | 2.0 ± 1.5                  | 2.5 ± 1.5                   | 1.8 ± 1.5                 | 0.058       |
| BMI (kg/m²) ± SD     | 27.8 ± 4.9                  | 28.1 ± 5.4                  | 27.6 ± 4.8                | NS          |
| Diabetes type 1      | 8% (8)                      | 12% (3)                     | 7% (5)                   | NS          |
| Diabetes type 2      | 30% (30)                    | 36% (9)                     | 28% (17)                 | NS          |
| COPD                 | 17% (17)                    | 20% (5)                     | 16% (12)                 | NS          |
| Stroke               | 10% (10)                    | 4% (1)                      | 12% (9)                  | NS          |
| Dose furosemide      |                             |                             |                          |             |
| Total dose (mg) ± SD | 63 ± 51                     | 86 ± 81                     | 53 ± 26                  | 0.049       |
| ≤40 mg/day           | 65% (65)                    | 44% (11)                    | 72% (54)                 | 0.014       |
| >40 mg/day           | 34% (34)                    | 56% (14)                    | 27% (20)                 |             |
| Total dose MRA (mg)  | 21 ± 11                     | 21 ± 12                     | 20 ± 11                  | NS          |
| Prescribed ARB/ARNI  | 38% (39)                    | 32% (8)                     | 41% (31)                 | NS          |
| Prescribed fluid restriction | 94% (94) | 96% (24)                     | 93% (70)                 | NS          |
| Fluid restriction 1500 mL | 32% (32) | 32% (8)                     | 32% (24)                 | NS          |
| Fluid restriction 1500–2000 mL | 37% (37) | 36% (9)                     | 37% (28)                 | NS          |
| I limit my fluid intake (EHFSCBS-5) | | | | |
| Totally agree/agree  | 79% (79)                    | 76% (19)                    | 80% (60)                 | NS          |
| Prescribed sodium restriction | 97% (97) | 100% (23)                   | 96% (72)                 | NS          |
| I eat a low salt diet (EHFSCBS-7) | | | | |
| Totally agree/agree  | 79% (79)                    | 80% (20)                    | 79% (59)                 | NS          |
| Glucose (blood) (mmol/L) ± SD | 7.0 ± 3.3 | 7.6 ± 4.4                   | 6.8 ± 2.9                | NS          |
| Sodium (blood) (mmol/L) ± SD | 140 ± 2.8 | 140 ± 2.8                   | 140 ± 2.7                | NS          |
| Potassium (blood) (mmol/L) ± SD | 4.6 ± 0.6 | 4.4 ± 0.6                   | 4.6 ± 0.6                | NS          |
| Creatinine (blood) (μmol/L) ± SD | 111.4 ± 39.9 | 108.8 ± 40.3               | 112.3 ± 40               | NS          |
| Urea (blood) (mmol/L) ± SD | 10.7 ± 5.7 | 11.5 ± 7.1                  | 10.4 ± 5.2               | NS          |
| NT-proBNP (blood) (pmol/L) ± SD | 209 ± 243 | 203 ± 205                   | 211 ± 256                | NS          |
| eGFR (blood) (mL/min/1.73 m²) ± SD | 55.1 ± 18.3 | 58.7 ± 19.7               | 54 ± 18                  | NS          |
| Urine total mL/24 h ± SD | 1755 ± 534 | 2043 ± 599                 | 1655 ± 474               | <0.01       |
| Sodium (urine) mmol/24 h ± SD | 121.6 ± 55.1 | 134 ± 64                   | 117.3 ± 51.4             | NS          |

ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration; EHFSCB, European Heart Failure Self-Care Behaviour Scale; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, amino-terminal-pro brain natriuretic peptide; NYHA, New York Heart Association Functional class; SD, standard deviation.
class between patients who completed the food diary and those who did not. The mean thirst score of the 100 patients in the study was 28 ± 25 (VAS 0–100); patients who had severe thirst had a mean score of 53 ± 29 (Table 1).

The majority of patients (94%) were prescribed a fluid restriction; 37% had a restriction between 1500–2000 mL and 32% a restriction of 1500 mL. Almost all of them (97%) also were prescribed a sodium restriction. Most of the patients (79%) reported to adhere to these prescriptions and reported to limit their fluid intake and eat a low salt diet (Table 1).

Data of the HF patients who completed the food diary (N = 68) are presented in Table 2.

The mean fluid intake of patients who completed a food diary (N = 68) was 1823 ± 459 mL and the mean sodium intake was 2168 ± 958 mg. The mean fluid intake of patients with severe and low thirst is presented in Figure 2.

### Table 2: Characteristics of HF patients who completed a food diary (N = 68)

|                          | All patients (N = 68) | Severe thirst (N = 16) | Low thirst (N = 52) |
|--------------------------|-----------------------|------------------------|---------------------|
| Age ± SD                 | 72 ± 11               | 71 ± 14                | 72 ± 11             |
| Female sex               | 38% (26)              | 25% (4)                | 42% (22)            |
| Thirst score ± SD        | 28 ± 23               | 50 ± 27                | 20 ± 15             |
| NYHA class               |                       |                        |                     |
| II                       | 77% (52)              | 75% (12)               | 77% (40)            |
| III-IV (>NYHA II)        | 21% (14)              | 19% (3)                | 21% (11)            |
| BMI (kg/m²) ± SD         | 27.8 ± 5.3            | 27.6 ± 5.9             | 27.9 ± 5.1          |
| LVEF ± SD                | 39% (13.5)            | 38 ± 15.3              | 39% (15.3)          |
| LVEF < 40%               | 50% (34)              | 50% (34)               | 56% (9)             |
| LVEF > 40%               | 43% (29)              | 43% (29)               | 37% (6)             |
| Ischaemic heart disease  | 47% (32)              | 44% (7)                | 48% (25)            |
| HF symptoms              |                       |                        |                     |
| Dyspnoea at rest         | 16% (11)              | 38% (6)                | 10% (5)             |
| Dyspnoea exercise        | 75% (51)              | 88% (14)               | 71% (37)            |
| Fatigue                  | 38% (26)              | 63% (10)               | 31% (16)            |
| Sleeping problems        | 31% (21)              | 38% (6)                | 26% (15)            |
| Total HF symptoms ± SD   | 1.9 ± 1.3             | 2.5 ± 1.5              | 1.7 ± 1.2           |
| Diabetes type 1          | 4% (3)                | 0% (0)                 | 6% (3)              |
| Diabetes type 2          | 26% (18)              | 31% (5)                | 25% (13)            |
| COPD                     | 13% (9)               | 19% (3)                | 12% (6)             |
| Stroke                   | 10% (7)               | 6% (1)                 | 12% (6)             |
| Dose furosemide          |                       |                        |                     |
| Total dose (mg) ± SD     | 64 ± 57               | 95 ± 93                | 51 ± 26             |
| <40 mg/day               | 69% (47)              | 38% (6)                | 79% (41)            |
| >40 mg/day               | 31% (21)              | 63% (10)               | 21% (11)            |
| Total dose MRA (mg) ± SD | 20 ± 10               | 20 ± 6                 | 21 ± 11             |
| Prescribed ARB/ARNI (yes)| 44% (30)              | 38% (6)                | 46% (24)            |
| Prescribed fluid restriction| 97% (66)           | 100% (16)              | 96% (50)            |
| Fluid restriction 1500 mL| 37% (25)              | 44% (7)                | 35% (18)            |
| Fluid restriction 1500–2000| 38% (26)            | 37% (6)                | 38% (20)            |
| I limit my fluid intake (HFSCBS-5) | | | |
| Totally agree/agree      | 88% (60)              | 88% (14)               | 88% (46)            |
| Fluid intake Day 1 ± SD  | 1894 ± 608            | 2026 ± 821             | 1853 ± 529          |
| Fluid intake Day 2 ± SD  | 1785 ± 525            | 1913 ± 534             | 1745 ± 521          |
| Fluid intake Day 3 ± SD  | 1777 ± 438            | 1903 ± 434             | 1739 ± 436          |
| Mean fluid intake in mL/24 h (3 days) ± SD | 1823 ± 459 | 1944 ± 475 | 1785 ± 451 |
| Prescribed sodium restriction | 99% (67)               | 100% (16)              | 98% (51)            |
| Sodium intake Day 1 ± SD | 2214 ± 1214           | 2221 ± 908             | 2211 ± 1301         |
| Sodium intake Day 2 ± SD | 2174 ± 905            | 2345 ± 765             | 2120 ± 944          |
| Sodium intake Day 3 ± SD | 2168 ± 958            | 2773 ± 1072            | 1987 ± 852          |
| Mean sodium intake in mg/24 h (3 days) ± SD | 2180 ± 691 | 2435 ± 666 | 2100 ± 686 |
| I eat a low salt diet (HFSCBS-7) | | | |
| Totally agree/agree      | 85% (58)              | 87% (14)               | 85% (58)            |
| Glucose (blood) (mmol/L) ± SD | 6.6 ± 2.6            | 6.5 ± 2.3              | 6.6 ± 2.7           |
| Sodium (blood) (mmol/L) ± SD | 140 ± 2.8             | 140.7 ± 2.5            | 139.7 ± 2.8         |
| Creatinine (blood) (µmol/L) ± SD | 109 ± 38             | 100 ± 25               | 112 ± 41            |
| Potassium (blood) (mmol/L) ± SD | 4.6 ± 0.6             | 4.4 ± 0.5              | 4.7 ± 0.5           |
| Urea (blood) (mmol/L) ± SD | 10.4 ± 4.8            | 10.3 ± 4.5             | 10.2 ± 5.0          |
| NT-proBNP (blood) (pmol/L) ± SD | 184 ± 170            | 200 ± 209              | 180 ± 158           |
| eGFR (blood) (mL/min/1.73 m²) ± SD | 56 ± 18              | 64 ± 17                | 54 ± 18             |
| Urine total mL/24 h ± SD  | 1824 ± 549            | 2216 ± 589             | 1700 ± 478          |
| Sodium (urine) (mmol/24 h) ± SD | 127.4 ± 72.7         | 148.1 ± 68             | 120.8 ± 52          |

AR, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration; HFSCBS, European Heart Failure Self-Care Behaviour Scale; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, amino-terminal-pro brain natriuretic peptide; NYHA, New York Heart Association Functional class; SD, standard deviation.
We compared the mean fluid intake with the prescribed restriction and found that 62% (N = 42) of the patients were non-adherent to their prescribed restriction, 43% (N = 29) drank more than their restriction, and 19% (N = 13) drank less than the prescription (refer to Figure 3). Patients who drank more than the prescribed fluid restriction were more thirsty compared with patients who were adherent or drank less than their prescription. Patients who were adherent (N = 23) had a mean thirst score of 23 ± 17. Non-adherent patients who drank more than the prescribed fluid restriction had a thirst score of 34 ± 26, and those who drank less than their restriction had a score of 26 ± 25. These differences however were not statistically significant.

Finally, we compared the mean sodium intake with the prescribed restriction, which was a maximum of 2400 mg sodium for all patients in the study. Most of the patients (77%) were adherent to this restriction. Adherent patients had a mean thirst score of 29 ± 25 compared with 28 ± 25 of patients who were non-adherent, which was not statistically significant.

**Factors associated with severe thirst in the total study population (N = 100)**

Patients with severe thirst had a significantly higher thirst score 53 ± 29 compared with patients with low thirst (28 ± 23). Patients with severe thirst also were prescribed with a higher dose of loop diuretics and suffered more often from fatigue (64% vs. 31%; P = 0.015). Finally, they had a higher amount of urine output over 24 h (2043 ± 599 mL; vs. 1655 ± 474 mL; P < 0.01) There were no significant differences in 24 h urinary sodium excretion and other clinical variables between the two groups.

In a multivariable logistic regression analysis, only a higher dose of loop diuretics [odds ratio 3.25; 95% confidence interval (CI) 1.01–10.45; P = 0.048] and the total amount of urine output (odds ratio 1.002; 95% CI 1.00–1.003; P = 0.010) remained statistically significant (Table 3), meaning that
Factors associated with real thirst in patients who completed the food diary (N = 68)

There were 68 patients who completed a food diary. Patients with severe thirst had a higher dose of loop diuretics and a higher sodium intake on one of the 3 days (2773 vs. 1987; \( P < 0.01 \)). They also experienced more often dyspnoea at rest (38% vs. 10%; \( P = 0.020 \)) and fatigue (63% vs. 31%; \( P = 0.03 \)). Twenty-four hours urinary sodium excretion was higher in patients with severe thirst, although urinary sodium excretion was not significantly different between the two groups.

In a multivariable logistic regression analysis, severe thirst remains independently associated with a higher dose of loop diuretic (odds ratio 22.7; 95% CI 2.78–185.0; \( P = 0.004 \)), a higher sodium intake (odds ratio 1.002; 95% CI 1.001–1.003; \( P = 0.003 \)) and more fatigue (odds ratio 11.2; 95% CI 1.54–82.12; \( P = 0.017 \)) (Table 4).

### Discussion

This is the first study that examines thirst in HF patients and the association with registered fluid intake and sodium intake as well as with other clinical and demographic characteristics.

We found that a quarter of all patients suffered from severe thirst. A study of Eng et al.\(^{16}\) even found a higher percentage of HF patients (47%) that were frequently thirsty with a median thirst score on the VAS scale of 50, although patients in that study were younger (mean age 67 compared with 72 in our study) and were recruited in a Mediterranean area. Patients in our study were included in 23 months, so there was not a specific season in which data were collected. Therefore, a seasonal or weather effect in our study is not expected.

Patients with severe thirst in our study were prescribed a higher dose of loop diuretics, produced a higher amount of urine in 24 h, had a higher sodium intake on 1 day and more often suffered from fatigue than patients with low thirst. Also urinary sodium excretion was higher, although not statistically significant.

Higher dose of diuretics might be an indication for more severe HF, although we did not find differences in NYHA-functional class or renal function between both groups. The association between thirst and dose of diuretics was also found in other studies.\(^{16,17}\)

We found an association between severe thirst and actual sodium intake, although this was only for 1 day of the food diary. All patients in the study were advised to restrict their sodium intake, mostly to a maximum of 6 g salt (2400 mg sodium). The majority of patients (85%) reported to eat a low salt diet. The recommended sodium intake and the self-reported restriction of sodium in the food did correspond to the mean sodium intake in patients who completed the food diary for 3 days, which was 2180 mg per day. This is lower compared with the mean sodium intake of the total Dutch population of 9 g salt (3600 mg sodium).\(^{18}\)

In a study on thirst in three different countries, Japanese patients reported that the intake of salt and spicy food was the main reason for their thirst.\(^{17}\) The mean salt intake in Japan however, was much higher (10–14 g salt/day) than in the Netherlands.\(^{19}\)

We also found that patients with severe thirst less often were prescribed an angiotensin receptor blocker (ARB) or angiotensin receptor neprilysin inhibitor, although these differences were not statistically significant. It is suggested that an ARB, leading to an inhibition of the angiotensin-II, also inhibits the thirst centre in the brain, leading to less thirst. Eng et al.\(^{16}\) found this association between thirst and prescribed ARB.

We expected to find an association between fluid restriction and thirst, because we previously described such a relationship that was also found in other studies.\(^{12,13,16,17}\) However, almost all patients in our study (97%) were advised to limit their fluid intake. The majority of the patients (79%) also reported to limit their fluid intake although data of the food diary showed that many patients did not adhere to the prescription. Patients with severe thirst did have a higher mean fluid intake, probably because of their thirst, compared with those with low thirst (1785 mL vs. 1944 mL). This difference, however, was not statistically significant. There were also no significant differences in thirst between adherent and non-adherent patients, but this was probably due to the small sample size.

### References

1. Eng et al. (2010) Thirst in heart failure: a systematic review and meta-analysis. Circ Heart Fail. 2010; 3: 218–227.
2. ESC Heart Failure 2022; 9: 2181–2188
3. DOI: 10.1002/ehf2.13960

---

| Table 3 Variables independently associated with severe thirst in patients with heart failure (N = 100) |
|--------------------------------------------------|
| Variable                           | Odds ratio | 95% Confidence interval | P value |
|------------------------------------|------------|-------------------------|---------|
| Higher dose of loop diuretics      | 3.25       | 1.01–10.45              | 0.048   |
| Total amount of urine/24 h         | 1.002      | 1.000–1.003             | 0.010   |
| Fatigue                            | 3.33       | 0.99–11.09              | 0.051   |

| Table 4 Variables independently associated with severe thirst in patients with heart failure (N = 68) |
|--------------------------------------------------|
| Variable                           | Odds ratio | 95% Confidence interval | P value |
|------------------------------------|------------|-------------------------|---------|
| Higher dose of loop diuretics      | 22.69      | 2.78–185.04             | 0.004   |
| Sodium intake                      | 1.002      | 1.001–1.003             | 0.003   |
| Fatigue                            | 11.2       | 1.54–82.12              | 0.017   |

*Dyspnoea at rest* and *Total amount of urine/24 h* were not significant in multivariable analysis.
Although all patients in our study were in a stable condition due to the inclusion criteria and 74% of the patients were in NYHA-functional class II, remarkably, almost all patients were prescribed a fluid restriction.

In the ESC Heart Failure Guidelines at the time of this study, a fluid restriction of 1500–2000 mL is not recommended routinely but could be considered, only in those patients with severe HF to relieve symptoms and congestion. In daily practice, however, a fluid restriction is still often prescribed, and moreover, many stable HF patients are still advised to limit their fluid intake.

We did not find an association between severe thirst and other demographic or clinical variables, for example age, diabetes, or renal function, which also can cause more thirst.

We realize that there could be other variables that might influence the severity of thirst in HF patients. However, this is the first study in which the actual fluid and sodium intake is related to thirst in HF patients. In future studies, it will be important to verify our findings in other populations, where food intake and weather conditions should be taken into account.

Although we found some associations with severe thirst in HF patients, notably, there is not a specific profile of the ‘severe thirsty patient’. Only the dose of loop diuretics was significantly related to thirst. When we aim to decrease this severe thirst in a stable HF population, it is advocated to review critically the dose of prescribed diuretics and try to decrease the dose if possible. Another option to decrease severe thirst is to consider whether a fluid restriction is necessary for all stable patients. If a fluid restriction is really needed, a more liberal intake of 30 to 35 mL/kg of body weight might cause less thirst as was found in the study of Waldrėus et al.

Although a stringent sodium restriction did not prevent fluid overload and adverse outcomes in patients with HF as was recently found in the SODIUM-HF study, some restriction of sodium intake and spicy food can be an intervention to prevent symptoms of thirst as some patients themselves suggested in another study.

### Strengths and limitations

This observational study has provided detailed clinical and laboratory data, including analysis of 24 h urine collection. In the majority of HF patients, also food diaries for three consecutive days were collected. Thirst distress and self-care behaviour were quantified by specific scales. However, several limitations should be mentioned. The cross-sectional study did not provide follow-up data on HF management and outcomes. Finally, the sample size of patients who completed the food diary was rather small (68), and therefore, it is possible that we did not found all factors associated with severe thirst.

### Conclusion and implications for daily practice

In this study, we found that a quarter of HF patients experienced severe thirst, which was associated with a higher dose of diuretics, HF symptoms, and more urine production.

In daily practice, it is important to realize that thirst is an important problem for HF patients. To decrease this troublesome symptom, it might be advocated to review timely the dose of diuretics. It is also suggested to reconsider a fluid restriction and adapt it to a more liberal intake.

### Acknowledgement

We acknowledge the HF nurses in the ZGT hospitals who included all patients in the study: E. Rodijk, A. Kleberger, T. Konings, and M. Bultje.

### Conflict of interest

All authors declared no conflict of interest.

### References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Molinaro M, O’Connor CM, Pfeffer M, Ponikowski P, Ruschitzka F, Rutten FH, van der Meer P, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016; 37: 2129–2200.

2. Zhang J, Hobkirk J, Carroll S, Pellicori P, Clark AL, Cleland JGF. Exploring quality of life in patients with and without heart failure. *Int J Cardiol*. 2016; 202: 676–684.

3. Reilly CM, Meadows K, Dunbar S. Thirst and QOL in persons with heart failure. *Heart Lung*. 2010; 4: 353.

4. Sholli M, Fiuzaat M, Cani D, O’Connor CM. Depression and heart failure: the lonely comorbidity. *Eur J Heart Fail*. 2020; 22: 2007–2017.

5. Waldrėus N, Sjöstrand F, Hahn RG. Thirst in the elderly with and without heart failure. *Arch Gerontol Geriatr*. 2011; 53: 174–178.

6. Andreae C, van der Wal MHL, van Veldhuisen DJ, Yang B, Stromberg A, Jaarsma T. Changes in appetite during the heart failure trajectory and association with fatigue, depressive symptoms, and quality of life. *J Cardiovasc Nurs*. 2021; 36: 539–545.

7. Toto RH. Regulation of plasma osmolality: thirst and vasopressin. *Crit Care Nurs Clin North Am*. 1994; 6: 661–674.

DOI: 10.1002/ehf2.13960
8. Allida SM, Inglis SC, Davidson PM, Lal S, Hayward CS, Newton PJ. Thirst in chronic heart failure: a review. *J Clin Nurs.* 2015; 24: 916–926.

9. Eng SH, Waldréus N, González B, Ehrlin J, Díaz V, Rivas C, Velayos P, Puertas M, Ros A, Martín P, Lupón J, Bayes-Genis A, Jaarsma T. Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. *ESC Heart Failure.* 2021; 8: 2192–2501.

10. Waldréus N, Hahn RG, Lyngå P, van der Wal MHL, Hägglund E, Jaarsma T. Changes in thirst intensity during optimization of heart failure medical therapy by nurses at the outpatient clinic. *J Cardiovasc Nurs.* 2016; 31: 17–24.

11. Johansson P, van der Wal MHL, Strömberg A, Waldréus N, Jaarsma T. Fluid restriction in patients with heart failure: how should we think? *Eur J Cardiovasc Nurs.* 2016; 15: 301–304.

12. Holst M, Strömberg A, Lindholm M, Willenheimer R. Liberal versus restricted fluid prescription in stabilised patients with chronic heart failure: result of a randomised cross-over study of the effects on health-related quality of life, physical capacity, thirst and morbidity. *Scand Cardiovasc J.* 2008; 42: 316–322.

13. Aliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. *JAMA Intern Med.* 2013; 173: 1058–1064.

14. Waldréus N, Jaarsma T, van der Wal MH, Kato NP. Development and psychometric evaluation of the Thirst Distress Scale for patients with heart failure. *Eur J Cardiovasc Nurs.* 2018; 17: 226–234.

15. Jaarsma T, Arestedt KF, Mårtensson J, Dracup K, Strömberg A. The European heart failure self-care behaviour scale revised into a nine-item scale (EHFScB-9): a reliable and valid international instrument. *Eur J Heart Fail.* 2009; 11: 99–105.

16. Eng SH, Jaarsma T, Lupón J, González B, Ehrlín J, Díaz V, Bayes-Genis A, Waldréus N. Thirst and factors associated with frequent thirst in patients with heart failure in Spain. *Heart Lung.* 2021; 50: 86–91.

17. van der Wal MHL, Waldréus N, Jaarsma T, Kato NP. Thirst in patients with heart failure in Sweden, the Netherlands, and Japan. *J Cardiovasc Nurs.* 2020; 35: 19–25.

18. Kloss L, Dawn Meyre J, Graeve L, Vetter W. Sodium intake and its reduction by food reformulation in the European Union—a review. *NFS J.* 2015; 1: 9–19.

19. Elliot P, Brown I. Sodium intakes around the World. Report of the World Health Organization. In *Background Document Prepared for the Forum and Technical Meeting on Reducing Salt Intake in Populations.* Paris: WHO Press Geneva; 2006.

20. Ezekowitz JA, Colin-Ramirez E, Ross H, Escobedo J, Macdonald P, Troughton R, Saldarriaga C, Alemayehu W, McAlister FA, Arcand J, Atherton J, On behalf of the SODIUM-HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. *The Lancet.* Published online ahead of April 2, 2022.